MCCRX
Price
$18.57
Change
-$0.08 (-0.43%)
Updated
Jul 31 closing price
Net Assets
592.58M
VSCIX
Price
$141.38
Change
-$0.34 (-0.24%)
Updated
Jul 31 closing price
Net Assets
188.57B
Interact to see
Advertisement

MCCRX vs VSCIX

MCCRX vs VSCIX Comparison Chart in %
View a ticker or compare two or three
VS
MCCRX vs. VSCIX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MCCRX is a Buy and VSCIX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VSCIX has more cash in the bank: 189B vs. MCCRX (593M). VSCIX pays higher dividends than MCCRX: VSCIX (1.23) vs MCCRX (0.03). MCCRX was incepted earlier than VSCIX: MCCRX (12 years) vs VSCIX (29 years). MCCRX (1.35) is less costly to investors than VSCIX (0.03). MCCRX is a more actively managed with annual turnover of: 40.00 vs. VSCIX (17.00). MCCRX has a lower initial minimum investment than VSCIX: MCCRX (0) vs VSCIX (5000000). VSCIX annual gain was more profitable for investors over the last year : 22.58 vs. MCCRX (13.27). VSCIX return over 5 years is better than : 35.13 vs. MCCRX (3.22).
MCCRXVSCIXMCCRX / VSCIX
Total Expense Ratio1.350.034,500%
Annual Report Gross Expense Ratio1.350.034,500%
Fund Existence12 years29 years-
Gain YTD16.49914.591113%
Front LoadN/AN/A-
Min. Initial Investment05000000-
Min. Initial Investment IRAN/AN/A-
Net Assets593M189B0%
Annual Yield % from dividends0.031.232%
Returns for 1 year13.2722.5859%
Returns for 3 years15.3243.4435%
Returns for 5 years3.2235.139%
Returns for 10 years41.28156.0726%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSPKX20.050.12
+0.60%
Goldman Sachs US Eq Div and Prem Instl
GSIQX23.62N/A
N/A
Goldman Sachs GQG Ptnrs Intl Opps R
HSIIX29.59-0.08
-0.27%
Carillon Eagle Small Cap Growth I
CCWSX21.56-0.16
-0.74%
Baird Chautauqua International Gr Inv
RYCFX49.56-1.15
-2.27%
Rydex Biotechnology C